@article {Ederjrheum.130949, author = {Lihi Eder and Jai Jayakar and Arane Thavaneswaran and Amir Haddad and Vinod Chandran and David Salonen and Cheryl F. Rosen and Dafna D. Gladman}, title = {Is the Madrid Sonographic Enthesitis Index Useful for Differentiating Psoriatic Arthritis from Psoriasis Alone and Healthy Controls?}, elocation-id = {jrheum.130949}, year = {2014}, doi = {10.3899/jrheum.130949}, publisher = {The Journal of Rheumatology}, abstract = {Objective To assess the usefulness of the MAdrid Sonographic Enthesitis Index (MASEI) in classifying patients as having psoriatic arthritis (PsA) and comparing entheseal abnormalities between patients with PsA, psoriasis alone (PsC), and healthy controls (HC). Methods Patients with PsC were assessed to exclude inflammatory arthritis. The MASEI scoring system was used to quantify the extent of ultrasonographic (US) entheseal abnormalities. The total MASEI score was categorized into items that reflected inflammatory abnormalities (MASEI-inflammatory) and chronic damage (MASEI-damage). Nonparametric tests were used to compare MASEI scores across the groups. A cutoff point of MASEI >= 20 was used to calculate the sensitivity and specificity of the MASEI to classify patients as having PsA. Results Patients with PsA (n = 50), PsC (n = 66), and HC (n = 60) were assessed. Total MASEI scores were higher in patients with PsA than in those with PsC, and both those groups were higher than HC (p \< 0.0001). MASEI-inflammatory showed a similar trend (p \< 0.0001). MASEI-damage was higher in patients with PsA compared to both patients with PsC and HC (p \< 0.0001); however, no difference was observed between patients with PsC and HC. No significant difference in MASEI scores was found across the 3 groups in patients with a body mass index \> 30. The sensitivity of the MASEI score to correctly classify patients as having PsA was 30\% and the specificity was 95\% when compared to HC and 89\% when compared to PsC. Conclusion The severity of US entheseal abnormalities is highest in patients with PsA followed by PsC and is lowest in healthy controls. MASEI can specifically classify patients as having PsA.}, issn = {0315-162X}, URL = {https://www.jrheum.org/content/early/2014/01/29/jrheum.130949}, eprint = {https://www.jrheum.org/content/early/2014/01/29/jrheum.130949.full.pdf}, journal = {The Journal of Rheumatology} }